The Advances and Challenges of NK Cell-Based Cancer Immunotherapy

Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clinical practice, but their efficacy is not sufficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Synat, Gao, Xuefeng, Zhang, Li, Yang, Erna, Li, Yonghui, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025748/
https://www.ncbi.nlm.nih.gov/pubmed/33652996
http://dx.doi.org/10.3390/curroncol28020105
_version_ 1783675548727246848
author Kang, Synat
Gao, Xuefeng
Zhang, Li
Yang, Erna
Li, Yonghui
Yu, Li
author_facet Kang, Synat
Gao, Xuefeng
Zhang, Li
Yang, Erna
Li, Yonghui
Yu, Li
author_sort Kang, Synat
collection PubMed
description Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clinical practice, but their efficacy is not sufficient to suppress tumor development mainly because of lacking specificity. To this end, the engineering of NK cells with T cell receptor along with CD3 subunits (TCR-NK) has been developed to increase the reactivity and recognition specificity of NK cells toward tumor cells. Here, we review recent advances in redirecting NK cells for cancer immunotherapy and discuss the major challenges and future explorations for their clinical applications.
format Online
Article
Text
id pubmed-8025748
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80257482021-04-08 The Advances and Challenges of NK Cell-Based Cancer Immunotherapy Kang, Synat Gao, Xuefeng Zhang, Li Yang, Erna Li, Yonghui Yu, Li Curr Oncol Review Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clinical practice, but their efficacy is not sufficient to suppress tumor development mainly because of lacking specificity. To this end, the engineering of NK cells with T cell receptor along with CD3 subunits (TCR-NK) has been developed to increase the reactivity and recognition specificity of NK cells toward tumor cells. Here, we review recent advances in redirecting NK cells for cancer immunotherapy and discuss the major challenges and future explorations for their clinical applications. MDPI 2021-02-26 /pmc/articles/PMC8025748/ /pubmed/33652996 http://dx.doi.org/10.3390/curroncol28020105 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Kang, Synat
Gao, Xuefeng
Zhang, Li
Yang, Erna
Li, Yonghui
Yu, Li
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
title The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
title_full The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
title_fullStr The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
title_full_unstemmed The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
title_short The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
title_sort advances and challenges of nk cell-based cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025748/
https://www.ncbi.nlm.nih.gov/pubmed/33652996
http://dx.doi.org/10.3390/curroncol28020105
work_keys_str_mv AT kangsynat theadvancesandchallengesofnkcellbasedcancerimmunotherapy
AT gaoxuefeng theadvancesandchallengesofnkcellbasedcancerimmunotherapy
AT zhangli theadvancesandchallengesofnkcellbasedcancerimmunotherapy
AT yangerna theadvancesandchallengesofnkcellbasedcancerimmunotherapy
AT liyonghui theadvancesandchallengesofnkcellbasedcancerimmunotherapy
AT yuli theadvancesandchallengesofnkcellbasedcancerimmunotherapy
AT kangsynat advancesandchallengesofnkcellbasedcancerimmunotherapy
AT gaoxuefeng advancesandchallengesofnkcellbasedcancerimmunotherapy
AT zhangli advancesandchallengesofnkcellbasedcancerimmunotherapy
AT yangerna advancesandchallengesofnkcellbasedcancerimmunotherapy
AT liyonghui advancesandchallengesofnkcellbasedcancerimmunotherapy
AT yuli advancesandchallengesofnkcellbasedcancerimmunotherapy

Ejemplares similares